IL-13 receptor-α2: A novel target for cancer therapy

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 321-327

  Joshi, Bharat H ^a   Puri, Raj K ^b  

^a Center for Biologics Evaluation and Research   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE TYK2; STAT6 PROTEIN;

CANCER RESEARCH; CANCER THERAPY; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; NEOPLASMS; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TH1-TH2 BALANCE;

EID: 77953443734     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.8     Document Type: Editorial

References (78)

1. Debinski W, Miner R, Leland P, Obiri NI, Puri RK: Receptor for interleukin (IL)13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271, 22428-22433 (1996).
2. Husain SR, Puri RK: Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 95, 3506-3513 (2000).
3. Joshi BH, Kawakami K, Leland P, Puri RK: Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8, 1948-1956 (2002).
4. Joshi BH, Plautz GE, Puri RK: Interleukin-13 receptor α chain: a novel tumor-associated transmembrane protein in primary expiants of human malignant gliomas. Cancer Res. 60, 1168-1172 (2000).
5. Kawakami K, Leland P, Puri RK: Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 60, 2981-2987 (2000). (Pubitemid 30395824)
6. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK: Interleukin-13 receptor α2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107, 1407-1418 (2006). (Pubitemid 44452792)
7. Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J. Biol. Chem. 270, 8797-8804 (1995).
8. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK: Role of interleukin-13 in cancer, pulmonary fibrosis, and other Th2-type diseases. Vitam. Horm. 74, 479-504 (2006).
9. Murata T, Obiri NI, Debinski W, Puri RK: Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 238, 90-94 (1997).
10. Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol. 158, 756-764 (1997). (Pubitemid 127492652)
11. Obiri NI, Murata T, Debinski W, Puri RK: Modulation of interleukin (IL)-13 binding and signaling by the γ c chain of the IL-2 receptor. J. Biol. Chem. 272, 20251-20258 (1997).
12. Junttila IS, Mizukami K, Dickensheets H et al.: Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity. J. Exp. Med. 205, 2595-2608 (2008)
13. Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97, 2673-2679 (2001).
14. Murata T, Noguchi PD, Puri RK: IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J. Immunol. 156, 2972-2978 (1996). (Pubitemid 126660646)
15. Murata T, Obiri NI, Puri RK: Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4-and IL-13-induced signal transduction. Int. J. Cancer 70, 230-240 (1997). (Pubitemid 27107422)
16. Murata T, Obiri NI, Puri RK: Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int. J. Mol. Med. 1, 551-557 (1998).
17. Murata T, Puri RK: Comparison of IL-13- and IL-4-induced signaling in EBV- immortalized human B cells. Cell. Immunol. 175, 33-40 (1997).
18. Murata T, Taguchi J Puri RK: Interleukin-13 receptor α′ but not a chain: a functional component of interleukin-4 receptors. Blood 91, 3884-3891 (1998). (Pubitemid 28225757)
19. Murata T, Taguchi J, Puri RK, Mohri H: Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int. J. Hematol. 69, 13-20 (1999).
20. Murata T, Noguchi PD, Puri RK: Receptors for interleukin (IL)-4 do not associate with the common γ chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J. Biol. Chem. 270, 30829-30836 (1995).
21. Kohler I, Alliger P, Minty A et al.: Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL4 sharing a DNA binding motif with an interferon-γ-induced nuclear binding factor. FEBS Lett. 345, 187-192 (1994). (Pubitemid 24188922)
22. Murata T, Husain SR, Mohri H, Puri RK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int. Immunol. 10, 1103-1110 (1998).
23. Kohler I, Alliger P, Rieber EP: Activation of gene transcription by IL-4, IL-13 and IFN-γ through a shared DNA binding motif. Behring Inst. Mitt. 78-86 (1995).
24. Lin JX, Migone TS, Tsang M et al.: The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331-339 (1995).
25. Ostrand-Rosenberg S, Grusby MJ, Clements VK: Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165, 6015-6019 (2000).
26. Blease K, Schuh JM, Jakubzick C et al.: Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am. J. Pathol. 160, 481-490 (2002).
27. Donaldson DD, Whitters MJ, Fitz LJ et al.: The murine IL-13 receptor α 2: molecular cloning, characterization, and comparison with murine IL-13 receptor α 1. J. Immunol. 161, 2317-2324 (1998).
28. Colotta F, Re F, Muzio M et al.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261, 472-475 (1993). (Pubitemid 23276556)
29. Mentink-Kane MM, Wynn TA: Opposing roles for IL-13 and IL-13 receptor α 2 in health and disease. Immunol. Rev. 202, 191-202 (2004).
30. Wynn TA: IL-13 effector functions. Annu. Rev. Immunol. 21, 425-456 (2003).
31. Wynn TA: Fibrotic disease and the Th1/Th2 paradigm. Nat. Rev. Immunol. 4, 583-594 (2004).
32. Zhang JG, Hilton DJ, Willson TA et al.: Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor α-chains. J. Biol. Chem. 272, 9474-9480 (1997).
33. Tabata Y, Chen W, Warrier MR, Gibson AM, Daines MO, Hershey GK: Allergy-driven alternative splicing of IL-13 receptor α2 yields distinct membrane and soluble forms. J. Immunol. 177, 7905-7912 (2006). (Pubitemid 44846306)
34. Kawakami M, Leland P, Kawakami K, Puri RK: Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol. Res. 12, 459-467 (2000).
35. Matsumura M, Inoue H, Matsumoto T et al.: Endogenous metalloprotease solubilizes IL-13 receptor α2 in airway epithelial cells. Biochem. Biophys. Res. Commun. 360, 464-469 (2007).
36. Chen W, Tabata Y, Gibson AM et al.: Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor α2 in vivo. J. Allergy Clin. Immunol. 122, 625-632 (2008).
37. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA: Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 34, 273-282 (2001).
38. Mentink-Kane MM, Cheever AW, Thompson RW et al.: IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc. Natl Acad. Sci. USA 101, 586-590 (2004).
39. Kioi M, Seetharam S, Puri RK: Targeting IL-13Rα2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol. Cancer Ther. 7, 1579-1587 (2008).
40. Kioi M, Seetharam S, Puri RK: N-linked glycosylation of IL-13R α2 is essential for optimal IL-13 inhibitory activity. FASEB J. 20, 2378-2380 (2006). (Pubitemid 44953833)
41. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ: IL-13Rα2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 62, 1103-1109 (2002). (Pubitemid 34160294)
42. Rahaman SO, Vogelbaum MA, Haque SJ: Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Rα2. Cancer Res. 65, 2956-2963 (2005).
43. Wood N, Whitters MJ, Jacobson BA et al.: Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α 2. J. Exp. Med. 197, 703-709 (2003).
44. Kawakami K, Takeshita F, Puri RK: Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor α 2 chain. J. Biol. Chem. 276, 25114-25120 (2001).
45. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A: IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat. Med. 12, 99-106 (2006).
46. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK: Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain. Cancer Res. 66, 4434-4442 (2006).
47. Eguchi J, Hatano M, Nishimura F et al.: Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 66, 5883-5891 (2006). (Pubitemid 43927143)
48. Ueda R, Low KL, Zhu X et al.: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J. Transl. Med. 5, 68 (2007).
49. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF: Expression of glioma-associated antigens in pediatric brain stem and non-brainstem gliomas. J. Neurooncol.88, 245-250 (2008).
50. Cooper LJ, Kalos M, DiGiusto D et al.: T-cell genetic modification for re-directed tumor recognition. Cancer Chemother. Biol. Response Modif. 22, 293-324 (2005).
51. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64, 9160-9166 (2004). (Pubitemid 39665531)
52. Minn AJ, Gupta GP, Siegel PM et al.: Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
53. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK: In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J. Exp. Med. 194, 1743-1754 (2001).
54. Terabe M, Matsui S, Noben-Trauth N et al.: NKT cell-mediated rexpression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1, 515-520 (2000).
55. Berzofsky JA, Terabe M: A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol. Immunother. 57, 1679-1683 (2008).
56. Joshi BH, Puri RK: Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr. Purif. 39, 189-198 (2005).
57. Puri RK, Leland P, Obiri NI et al.: Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87, 4333-4339 (1996). (Pubitemid 26155030)
58. Husain SR, Joshi BH, Puri RK: Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92, 168-175 (2001).
59. Husain SR, Obiri NI, Gill P et al.: Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3, 151-156 (1997).
60. Kawakami K, Husain SR, Bright RK, Puri RK: Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8, 861-868 (2001). (Pubitemid 33086533)
61. Kawakami K, Husain SR, Kawakami M, Puri RK: Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol. Med. 8, 487-494 (2002).
62. Kawakami M, Kawakami K, Puri RK: Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol. Immunother. 50, 691-700 (2002).
63. Kawakami K, Kawakami M, Puri RK: Cytokine receptor as a sensitizer for targeted cancer therapy. Anticancer Drugs 13, 693-699 (2002). (Pubitemid 34899207)
64. Kawakami M, Kawakami K, Puri RK: Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol. Cancer Ther. 1, 999-1007 (2002).
65. Kawakami K, Kawakami M, Puri RK: IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J. Immunol. 169, 7119-7126 (2002). (Pubitemid 36899301)
66. Kawakami K, Kawakami M, Joshi BH, Puri RK: Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61, 6194-6200 (2001). (Pubitemid 32762557)
67. Kawakami K, Kawakami M, Leland P, Puri RK: Internalization property of interleukin-4 receptor α chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells. Clin. Cancer Res. 8, 258-266 (2002).
68. Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK: Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Rα2-expressing contralateral tumors. Clin. Cancer Res. 12, 4678-4686 (2006).
69. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase 1 studies. Acta Neurochir. (Suppl. 88), 105-111 (2003).
70. Kunwar S, Chang SM, Prados MD et al.: Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg. Focus 20, E15 (2006).
71. Kunwar S, Prados MD, Chang SM et al.: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25, 837-844 (2007).
72. Parney IF, Kunwar S, McDermott M et al.: Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg. 102, 267-275 (2005). (Pubitemid 43194076)
73. Vogelbaum MA, Sampson JH, Kunwar S et al.: Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neurosurgery 61, 1031-1037; discussion 1037-1038 (2007). (Pubitemid 350306946)
74. Prados M, Kunwar S, Lang F et al.: Final results of Phase I/II studies of IL-13PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanceddelivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. J. Clin. Oncol. 23, 115S (2005).
75. Lang F, Kunwar S, Strauss L et al.: A clinical study of convection-enhanced delivery of IL-13PE38QQR cytotoxin pre- and post-resection of recurrent GBM. Presented at: American Society of Neuro-Oncologists. Chicago, IL, USA, 12-19 April 2002.
76. Prados M, Lang F, Sherman J et al.: Convection-Enhanced Delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL-13PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. J. Neurooncol. 4, S78 (2002).
77. Prados M, Lang F, Strauss L et al.: Intrtumoral and intracerebral microinfusion of Il13-PE38QQR cytotoxin: Phase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. J. Clin. Oncol. (2002).
78. Prados M, Lang F, Strauss L et al.: Pre and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: Phase I study in recurrent respectable malignant glioma. Presented at: First Qudrennial meeting - World Federation of Neuro-Oncology. Washington, DC, USA, 15-17 November 2001.